Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3187 - Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor: Exploratory analysis in the patients who were enrolled in JCOG0705/KGCA01 phase III trial (REGATTA) and could continue chemotherapy


29 Sep 2019


Poster Display session 2


Tumour Site

Gastric Cancer


Takaki Yoshikawa


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


T. Yoshikawa1, K. Fujitani2, H. Yang3, J. Mizusawa4, M. Terashima5, T. Tsujinaka6, K. Nakamura7, H. Katayama7, S. Jin8, S. Kong9, Y. Iwasaki10, H. Kim11, A. Takagane12, S. Lee13, J. Bae14, S.H. Noh15, M. Sasako16

Author affiliations

  • 1 Gastric Surgery, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Gastrointestinal Surgery, Osaka General Medical Center, Osaka/JP
  • 3 Surgery & Cancer Research Institute, Seoul National University Hospital, Seoul/KR
  • 4 Japan Clinical Oncology Group Data Center, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 5 Division Of Gastric Surgery, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 6 Surgery, Kaizuka City Hospital, 597-0015 - Kaizuka/JP
  • 7 Japan Clinical Oncology Group Operations Office, National Cancer Center Hospital, Tokyo/JP
  • 8 Surgery, Korea Cancer Center Hospital, Seoul/KR
  • 9 Department Of Surgery & Cancer Research Institute, Seoul National University Hospital, Seoul/KR
  • 10 Surgery, Komagome Tokyo Metropolitan Hospital, Tokyo/JP
  • 11 Surgery, Seoul National University Bundang Hospital, Seongnam/KR
  • 12 Surgery, Hakodate Goryokaku Hospital, Hakodate/JP
  • 13 Surgery, Kosin University Gospel Hospital, Pusan/KR
  • 14 Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR
  • 15 Surgery, Gangnam Severance Hospital, Seoul/KR
  • 16 Surgery, Yodogawa Christian Hospital, 533-0024 - Osaka/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3187


REGATTA is a phase III trial to compare chemotherapy alone (arm A) and reduction surgery followed by chemotherapy (arm B) for advanced gastric cancer with a single non-curable factor. The trial failed to show superiority of reduction surgery, which could be partially explained by poor compliance of chemotherapy in arm B. This exploratory analysis aims to clarify whether upfront surgery has survival benefit in patients (pts) who could continue chemotherapy for some period, enrolled in REGATTA.


In REGATTA, 175 pts were assigned to arm A (86 pts) and arm B (89 pts). S-1 80 mg/m2 for 3 weeks and CDDP 60 mg/m2 on day 8 was repeated every 6 weeks. The pts were limited to those for whom chemotherapy was continued at 2, 4, or 6 months after randomization (cohort-2M, cohort-4M, or cohort-6M, respectively) and pts who underwent gastrectomy in arm A were excluded. The overall survival (OS) was defined as the duration from the date at 2, 4, or 6 months after randomization to the date of the death from any cause or to the last date of contact for a surviving pt.


Examined pts were 130 (59 in arm A and 71 in arm B) in cohort-2M, 111 (50 in arm A and 61 in arm B) in cohort-4M, and 90 (43 in arm A and 47 in arm B) in cohort-6M, respectively. In cohort-2M, the median survival time (MST) was 14.1 months (m) (95% CI, 11.7-16.6) in arm A and 12.6 m (9.9-15.9) in arm B with hazard ratio (HR) of 0.935 (0.641-1.635). The OS was 9.7% (3.2-20.5) in arm A and 17.9% (9.2-28.8) in arm B at 3-year. In cohort-4M, the MST was 13.1 m (10.3-18.8) in arm A and 11.5 m (8.4-15.1) in arm B with HR of 0.954 (0.629-1.448). The OS was 11.5% (3.8-24.0) in arm A and 21.2% (11.0-33.6) in arm B at 3-year. In cohort-6M, the MST was 13.8 m (9.8-22.1) in arm A and 10.9 m (6.6-16.6) in arm B with HR of 0.860 (0.535-1.383). The OS was 13.2% (4.3-27.0) in arm A and 26.0% (13.1-41.0) in arm B at 3-year.


Among pts having certain period of chemotherapy, there seem to be more long survivors in arm B than the arm A. Reduction surgery may still be promising if chemotherapy compliance after surgery could be improved.

Clinical trial identification

UMIN000001012, Feb 2008.

Editorial acknowledgement

Legal entity responsible for the study

Japan Clinical Oncology Group (JCOG).


The Ministry of Health, Labour and Welfare of Japan and the Korean Gastric Cancer Association.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.